CellaVision has decided to launch a cell morphology system for the veterinary market in North America. The product, CellaVision ® DM96 Vet, is an adapted version of the company's existing instrument for human blood with the capability to analyze blood from the most common companion animals. The product will initially be marketed to larger veterinary laboratories in the U.S. and Canada, such as veterinary universities and commercial reference labs. The product will be available in the first quarter, and will be sold direct by the Company.
"The veterinary market has fewer large laboratories than the human market, but is interesting because we can sell an existing instrument with modified software. In the larger laboratory chains in the U.S. and Canada, both the volume of samples and the need for an efficient analytical method, are high, which gives us opportunities for further growth in the hematology segment. Globally the veterinary market is less consolidated as compared to the human market, but over time, expansion outside North America is possible," says Yvonne Mårtensson, CEO of CellaVision.
Laboratories that perform veterinary tests face the same challenges as their human counterparts, that is, increased demand for efficiency and quality. CellaVision's digital solution replaces a manual microscope and delivers considerable gains in productivity, test result quality and response times. These analyses often provide critical results used in the diagnosis of a variety of illnesses in both humans and animals such as infection and cancer.
Hematology testing is a key component of veterinary diagnostics. In North America, the majority of tests are from "companion animals", (i.e. Canine, Feline and Equine), and are performed in veterinary clinics, commercial reference laboratories or hospital laboratories. With the CellaVision DM96 Vet, CellaVision addresses the needs of the over 100 large veterinary laboratories throughout North America. Registration by FDA or Health Canada is not required to sell the product in the veterinary market.
For more information, please contact:
Yvonne Mårtensson, CEO, CellaVision AB
Tel: +46 708 33 77 82. E-mail: yvonne.martensson@cellavision.com (mailto:yvonne.martensson@cellavision.com)
About CellaVision
CellaVision is an innovative, global medical technology company that develops and sells best-in-class systems for the routine analysis of blood and other body fluids. These analyses often provide critical results used in the diagnosis of a variety of illnesses such as infection and cancer. CellaVision's products reduce manual laboratory work, standardize results and support an efficient laboratory workflow. The company has leading-edge expertise in digital image analysis, artificial intelligence and automated microscopy. In 2010, net sales were 132 MSEK and sales continue to grow with the target to increase by at least 15 percent per year over an economic cycle. CellaVision has its head office in Lund, Sweden, and subsidiaries in the US, Canada and Japan. The company share is listed on Nasdaq OMX Stockholm, Small Cap. Read more at www.cellavision.com (http://www.cellavision.com/).
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: CellaVision AB via Thomson Reuters ONE
